Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to ...

Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a ...

Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% ...

Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Piper Sandler analyst Adam Maeder upgraded shares of Nevro Corp (NYSE:NVRO), a medical device company with a market ...

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 ...

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its technological innovations and diversification plans regarding its product portfolio. The optimism, led by a solid ...